吉贝尔前三季度净利增逾12%，抗抑郁创新药III期临床试验获重大突破

Core Viewpoint - The company Gibeir reported its Q3 2025 financial results, showing a revenue increase and a decline in net profit for the third quarter, while also announcing promising results for its new antidepressant drug JJH201501 from Phase III clinical trials [1][2]. Financial Performance - For the first three quarters, the company achieved a revenue of 704 million yuan, representing a year-on-year growth of 9.52% [1]. - The net profit attributable to shareholders for the same period was 197 million yuan, up by 12.8% year-on-year [1]. - In Q3 alone, the company reported a revenue of 250 million yuan, which is a 19.08% increase compared to the same quarter last year [1]. - However, the net profit for Q3 was 47.5885 million yuan, reflecting a decrease of 9.45% year-on-year [1]. Drug Development - Gibeir announced the results of the Phase III clinical trial for its antidepressant drug JJH201501, which utilizes a deuterated drug development platform [1][2]. - The clinical efficacy of JJH201501 in the 10mg and 15mg groups was significantly better than the placebo group after 8 weeks of continuous use, with statistical significance [2]. - The efficacy of JJH201501 in both dosage groups was comparable to that of the 20mg group of hydrobromide vortioxetine [2]. - The company acknowledged the long, complex, and costly nature of new drug development, indicating that future progress may be subject to uncertainties [2].